盐酸阿那格雷胶囊治疗原发性血小板增多症临床研究  

Clinical Study of Anagrelide in the Treatment of Essential Thrombocythemia

作　　者：丁辉[1] 

机构地区：[1]河南大学淮河医院血液科,河南开封475000

出　　处：《中国继续医学教育》2016年第26期159-160,共2页China Continuing Medical Education

摘　　要：目的研究盐酸阿那格雷胶囊治疗原发性血小板增多症(ET)临床效果。方法选取来我院治疗ET的166例,随机分组,各83例,对照组给予羟基脲片治疗,观察组给予盐酸阿那格雷胶囊治疗,两组均治疗3个月,对比两组疗效与不良反应发生情况。结果治疗后,观察组总有效率为74.6%(62/83),对照组为60.2%(50/83),观察组高于对照组,差异有统计学意义(P<0.05);且不良反应发生率差异无统计学意义(P>0.05)。结论应用盐酸阿那格雷胶囊治疗ET,疗效显著,安全性较好。Objective To study the clinical effect of anagrelide in the treatment of. Essential Thrombocythemia （ET）. Methods 166 cases of ET treated in our hospital were selected, random grouping, each of 83 cases, the control group was given hydroxycarbamide tablets treatment, the observation group was treated with anagrelide, two groups were treated for 3 months, compared with two groups of curative effect and adverse reactions. Results After treatment, the total effective rate of the observation group was 74.6% （62/83）, the control group was 60.2% （50/83）, the observation group was significantly higher than the control group, the difference was statistically significant （P〈0.05）, there was no significant difference in the incidence of adverse reactions （P〉0.05）. Conclusion Application of anagrelide in the treatment of ET, the curative effect is remarkable, the security is good.

关 键 词：原发性血小板增多症 阿那格雷 疗效 

分 类 号：R914[医药卫生—药物化学]